Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Evoked Potentials, Auditory, Brain Stem | 7 | 2022 | 10 | 1.670 |
Why?
|
| Auditory Perception | 5 | 2018 | 66 | 1.530 |
Why?
|
| Hearing Loss, Noise-Induced | 3 | 2022 | 7 | 1.520 |
Why?
|
| Anura | 6 | 2021 | 34 | 1.270 |
Why?
|
| Deafness | 4 | 2023 | 7 | 1.220 |
Why?
|
| HIV Infections | 10 | 2025 | 2535 | 1.210 |
Why?
|
| Prisoners | 2 | 2025 | 95 | 1.020 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2025 | 172 | 1.020 |
Why?
|
| Auditory Threshold | 5 | 2022 | 7 | 0.970 |
Why?
|
| Homosexuality, Male | 5 | 2025 | 483 | 0.960 |
Why?
|
| Hearing Loss | 3 | 2020 | 16 | 0.960 |
Why?
|
| Noise | 4 | 2022 | 10 | 0.840 |
Why?
|
| Vocalization, Animal | 4 | 2017 | 54 | 0.690 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 825 | 0.650 |
Why?
|
| Physician Assistants | 3 | 2024 | 20 | 0.620 |
Why?
|
| Cochlear Nucleus | 1 | 2018 | 1 | 0.590 |
Why?
|
| Hyperkinesis | 1 | 2018 | 7 | 0.590 |
Why?
|
| Spiral Ganglion | 1 | 2018 | 6 | 0.590 |
Why?
|
| Diet | 5 | 2023 | 810 | 0.550 |
Why?
|
| Sex Factors | 3 | 2017 | 1008 | 0.520 |
Why?
|
| Male | 27 | 2025 | 22779 | 0.520 |
Why?
|
| Hearing | 5 | 2023 | 10 | 0.490 |
Why?
|
| Mice, Inbred CBA | 5 | 2022 | 41 | 0.480 |
Why?
|
| Behavior, Animal | 1 | 2018 | 369 | 0.480 |
Why?
|
| Peripheral Nervous System | 1 | 2015 | 14 | 0.460 |
Why?
|
| Acoustic Stimulation | 6 | 2022 | 74 | 0.450 |
Why?
|
| Siblings | 2 | 2024 | 22 | 0.430 |
Why?
|
| Body Size | 1 | 2014 | 47 | 0.420 |
Why?
|
| Female | 19 | 2025 | 24018 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 744 | 0.410 |
Why?
|
| Biomedical Research | 1 | 2017 | 467 | 0.380 |
Why?
|
| Animals | 20 | 2023 | 16695 | 0.380 |
Why?
|
| Young Adult | 8 | 2025 | 4936 | 0.370 |
Why?
|
| Humans | 28 | 2025 | 42163 | 0.350 |
Why?
|
| Hair Cells, Auditory | 3 | 2020 | 9 | 0.350 |
Why?
|
| Anti-HIV Agents | 3 | 2024 | 475 | 0.310 |
Why?
|
| Los Angeles | 4 | 2025 | 390 | 0.300 |
Why?
|
| Adult | 11 | 2025 | 13458 | 0.290 |
Why?
|
| Leadership | 3 | 2023 | 84 | 0.280 |
Why?
|
| Middle Aged | 10 | 2025 | 11819 | 0.270 |
Why?
|
| Mice | 7 | 2023 | 6490 | 0.250 |
Why?
|
| Peer Group | 2 | 2025 | 173 | 0.250 |
Why?
|
| Cochlea | 2 | 2022 | 6 | 0.220 |
Why?
|
| Vestibular Diseases | 1 | 2023 | 3 | 0.210 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2023 | 10 | 0.210 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 13 | 0.210 |
Why?
|
| Abnormalities, Multiple | 1 | 2023 | 38 | 0.210 |
Why?
|
| Face | 1 | 2023 | 41 | 0.200 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 263 | 0.200 |
Why?
|
| Sexual Behavior | 3 | 2025 | 634 | 0.200 |
Why?
|
| Food | 1 | 2023 | 102 | 0.190 |
Why?
|
| Nutrition Assessment | 1 | 2023 | 79 | 0.190 |
Why?
|
| Faculty | 1 | 2023 | 105 | 0.190 |
Why?
|
| Sexual Partners | 2 | 2022 | 325 | 0.190 |
Why?
|
| Social Support | 1 | 2025 | 438 | 0.190 |
Why?
|
| Echolocation | 1 | 2021 | 2 | 0.180 |
Why?
|
| United States | 6 | 2024 | 5072 | 0.180 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 74 | 0.180 |
Why?
|
| Chiroptera | 1 | 2021 | 23 | 0.180 |
Why?
|
| Physicians | 1 | 2023 | 180 | 0.180 |
Why?
|
| Psychoacoustics | 3 | 2020 | 5 | 0.180 |
Why?
|
| Animal Communication | 1 | 2021 | 7 | 0.180 |
Why?
|
| Education, Medical | 1 | 2022 | 117 | 0.180 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 118 | 0.170 |
Why?
|
| Aging | 3 | 2022 | 764 | 0.170 |
Why?
|
| Mole Rats | 1 | 2020 | 5 | 0.170 |
Why?
|
| Fatty Liver | 1 | 2021 | 71 | 0.170 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 11 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 959 | 0.160 |
Why?
|
| Sex Characteristics | 2 | 2020 | 253 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 471 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 1 | 2022 | 181 | 0.160 |
Why?
|
| Nerve Degeneration | 1 | 2020 | 108 | 0.160 |
Why?
|
| Species Specificity | 3 | 2015 | 279 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 1554 | 0.160 |
Why?
|
| Neurons | 3 | 2017 | 1246 | 0.160 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 135 | 0.150 |
Why?
|
| Curcumin | 1 | 2020 | 115 | 0.150 |
Why?
|
| Mexican Americans | 1 | 2021 | 224 | 0.150 |
Why?
|
| Analgesics, Opioid | 2 | 2013 | 245 | 0.150 |
Why?
|
| Thalamus | 1 | 2018 | 34 | 0.150 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 299 | 0.150 |
Why?
|
| Visual Cortex | 1 | 2018 | 65 | 0.140 |
Why?
|
| Visual Perception | 1 | 2018 | 75 | 0.140 |
Why?
|
| Long-Term Potentiation | 1 | 2018 | 109 | 0.140 |
Why?
|
| Inferior Colliculi | 1 | 2017 | 4 | 0.140 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 35 | 0.130 |
Why?
|
| Minority Groups | 1 | 2022 | 663 | 0.130 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2017 | 18 | 0.130 |
Why?
|
| Exercise | 1 | 2023 | 674 | 0.130 |
Why?
|
| Catecholamines | 1 | 2017 | 45 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3077 | 0.130 |
Why?
|
| Cornea | 2 | 1988 | 81 | 0.130 |
Why?
|
| Reaction Time | 2 | 2014 | 151 | 0.130 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2017 | 59 | 0.130 |
Why?
|
| Collagen | 2 | 1988 | 178 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2021 | 705 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 32 | 0.110 |
Why?
|
| Tympanic Membrane | 1 | 2014 | 1 | 0.110 |
Why?
|
| Sound Localization | 1 | 2014 | 4 | 0.110 |
Why?
|
| Electrophysiology | 1 | 2014 | 138 | 0.100 |
Why?
|
| Caudate Nucleus | 1 | 2013 | 22 | 0.100 |
Why?
|
| Macaca fascicularis | 1 | 2013 | 64 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2024 | 238 | 0.100 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2013 | 22 | 0.100 |
Why?
|
| Aged | 3 | 2023 | 7982 | 0.100 |
Why?
|
| Receptors, Opioid, mu | 2 | 2013 | 50 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 979 | 0.100 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 99 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2014 | 574 | 0.090 |
Why?
|
| Educational Status | 2 | 2023 | 335 | 0.090 |
Why?
|
| Models, Biological | 1 | 2014 | 711 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 577 | 0.080 |
Why?
|
| Research Design | 2 | 2023 | 370 | 0.070 |
Why?
|
| Keratoconus | 1 | 1988 | 18 | 0.070 |
Why?
|
| Opioid-Related Disorders | 1 | 2008 | 188 | 0.060 |
Why?
|
| Lung | 2 | 2021 | 484 | 0.060 |
Why?
|
| Child | 2 | 2023 | 3381 | 0.050 |
Why?
|
| Causality | 1 | 2023 | 45 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 12 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2023 | 65 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 100 | 0.050 |
Why?
|
| Faculty, Medical | 1 | 2022 | 74 | 0.050 |
Why?
|
| Intention | 1 | 2023 | 103 | 0.050 |
Why?
|
| Food Supply | 1 | 2023 | 120 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 733 | 0.050 |
Why?
|
| Eating | 1 | 2023 | 164 | 0.050 |
Why?
|
| Benzeneacetamides | 2 | 2013 | 6 | 0.040 |
Why?
|
| Fentanyl | 2 | 2013 | 16 | 0.040 |
Why?
|
| Adolescent | 3 | 2022 | 5950 | 0.040 |
Why?
|
| Pyrrolidines | 2 | 2013 | 30 | 0.040 |
Why?
|
| Viral Load | 1 | 2022 | 344 | 0.040 |
Why?
|
| Motivation | 1 | 2024 | 492 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 81 | 0.040 |
Why?
|
| Sirolimus | 1 | 2020 | 70 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2020 | 158 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 541 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 135 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 2020 | 75 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 487 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2024 | 1729 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 94 | 0.040 |
Why?
|
| Sensory Deprivation | 1 | 2018 | 7 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2020 | 162 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 1054 | 0.040 |
Why?
|
| Base Sequence | 1 | 2020 | 997 | 0.040 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2018 | 12 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 297 | 0.040 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2018 | 80 | 0.040 |
Why?
|
| Interneurons | 1 | 2018 | 64 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 661 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 133 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 599 | 0.030 |
Why?
|
| Auditory Pathways | 1 | 2017 | 10 | 0.030 |
Why?
|
| Sexual Behavior, Animal | 1 | 2017 | 64 | 0.030 |
Why?
|
| Methylation | 1 | 2017 | 118 | 0.030 |
Why?
|
| Staining and Labeling | 2 | 1988 | 106 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1597 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2017 | 135 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 837 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 246 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 933 | 0.030 |
Why?
|
| Tubocurarine | 1 | 2014 | 3 | 0.030 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2014 | 3 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2020 | 501 | 0.030 |
Why?
|
| Immobilization | 1 | 2014 | 11 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1420 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 51 | 0.030 |
Why?
|
| Vibration | 1 | 2014 | 23 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 35 | 0.030 |
Why?
|
| Pressure | 1 | 2014 | 49 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 2598 | 0.030 |
Why?
|
| Restraint, Physical | 1 | 2013 | 22 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2013 | 27 | 0.030 |
Why?
|
| Weight Gain | 1 | 2014 | 138 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 65 | 0.030 |
Why?
|
| Wakefulness | 1 | 2013 | 23 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1804 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 3942 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 428 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2013 | 89 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 170 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 2111 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 438 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1058 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 382 | 0.020 |
Why?
|
| Sulfur | 1 | 1989 | 21 | 0.020 |
Why?
|
| Reinforcement Schedule | 1 | 2008 | 15 | 0.020 |
Why?
|
| Spironolactone | 1 | 1989 | 36 | 0.020 |
Why?
|
| Self Administration | 1 | 2008 | 67 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2008 | 139 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 151 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2008 | 90 | 0.020 |
Why?
|
| Phenazines | 1 | 1988 | 6 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1988 | 47 | 0.020 |
Why?
|
| Azo Compounds | 1 | 1988 | 17 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 141 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 181 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2013 | 641 | 0.020 |
Why?
|
| Fixatives | 1 | 1986 | 6 | 0.020 |
Why?
|
| Corneal Diseases | 1 | 1986 | 11 | 0.020 |
Why?
|
| Reference Values | 1 | 1986 | 207 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1112 | 0.010 |
Why?
|
| Half-Life | 1 | 1989 | 63 | 0.000 |
Why?
|
| Biotransformation | 1 | 1989 | 68 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1989 | 458 | 0.000 |
Why?
|